Investing.com UK - Financial Markets Worldwide
🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

AstraZeneca Rises Amid Strong Performance in Tough Quarter

Published 30/04/2021, 17:04
© Reuters
C
-
AZN
-

By Christiana Sciaudone

Investing.com --  AstraZeneca (NASDAQ:AZN)'s American Depository Receipts rose 4% after handily beating expectations for its first quarter.

Earnings per share of $1.63 on sales of $7.32 billion beat estimates of 68 cents and $7.03 billion, respectively.  

Sales grew 15% and the company reiterated guidance for the full year, despite  restrictions in Europe against the use of its Covid-19 vaccine amid incidents of blood clots.  

Vaccine "shipments are increasing as manufacturing improves," Chief Executive Officer Pascal Soriot said during a media briefing, according to StreetInsider.

The company made $275 million from 68 million doses, and the company is on track to deliver 200 million doses each month.

Citigroup (NYSE:C) noted that the company's core business continues to perform above market expectations in a challenging quarter. 

Shares are down about 6% from a year ago.

 

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.